We are live on ! Find out more
DMAC icon

DiaMedica Therapeutics
DMAC

25 hedge funds and large institutions have $3.93M invested in DiaMedica Therapeutics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 4

0% more capital invested

Capital invested by funds: $3.92M → $3.93M (+$6.38K)

0.15% more ownership

Funds ownership: 9.55% → 9.7% (+0.15%)

11% less funds holding

Funds holding: 28 → 25 (-3)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
25
Holders Change
-3
Holders Change %
-10.71%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
9
Reduced
4
Closed
4
Calls
$13K
Puts
–
Net Calls
+$13K
Net Calls Change
+$21K

Top Buyers

Rank Fund Capital Flow
1
CLG
Cooperman Leon G
+$88.7K
2
Renaissance Technologies
Renaissance Technologies
New York
+$49K
3
CFP
Catalyst Financial Partners
Massachusetts
+$16.9K
4
Citadel Advisors
Citadel Advisors
Florida
+$4.79K
5
TRCT
Tower Research Capital (TRC)
New York
+$3.65K

Top Sellers

Rank Fund Capital Flow
1
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$40.7K
2
Jane Street
Jane Street
New York
-$32.9K
3
Two Sigma Investments
Two Sigma Investments
New York
-$19.2K
4
Northern Trust
Northern Trust
Illinois
-$3.56K
5
UBS Group
UBS Group
Switzerland
-$2.73K
Name Holding Trade Value Shares
Change 		Change in
Stake
CLG
1
Cooperman Leon G
$1.33M +$88.7K +55,905 +7%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.2M – – –
JAMONY
3
Jacob Asset Management of New York
California
$358K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$283K – – –
Northern Trust
5
Northern Trust
Illinois
$139K -$3.56K -2,243 -2%
BlackRock
6
BlackRock
New York
$110K +$2.75K +1,733 +2%
State Street
7
State Street
Massachusetts
$102K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$99K +$49K +30,889 +92%
Morgan Stanley
9
Morgan Stanley
New York
$87.5K +$3.15K +1,987 +4%
Citadel Advisors
10
Citadel Advisors
Florida
$64.6K +$4.79K +3,018 +8%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$55.2K – – –
CFP
12
Catalyst Financial Partners
Massachusetts
$38.4K +$16.9K +10,635 +73%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$25.9K -$40.7K -25,675 -60%
TRCT
14
Tower Research Capital (TRC)
New York
$9K +$3.65K +2,302 +62%
MPWT
15
MassMutual Private Wealth & Trust
Connecticut
$7.38K – – –
US Bancorp
16
US Bancorp
Minnesota
$6.63K – – –
Simplex Trading
17
Simplex Trading
Illinois
$5K -$1.65K -1,037 -23%
BNP Paribas Financial Markets
18
BNP Paribas Financial Markets
France
$3.37K +$2.54K +1,604 +267%
UBS Group
19
UBS Group
Switzerland
$3.12K -$2.73K -1,719 -46%
TWC
20
TD Waterhouse Canada
Ontario, Canada
$3.1K – – –
LFA
21
Legend Financial Advisors
Pennsylvania
$1.53K – – –
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
$1K – – –
FDCDDQ
23
Federation des caisses Desjardins du Quebec
Quebec, Canada
$352 – – –
Wells Fargo
24
Wells Fargo
California
$171 +$3 +2 +2%
Jane Street
25
Jane Street
New York
– -$32.9K -20,840 Closed
1
2

DMAC Hedge Fund Activity: Q1 2023 in Review

25 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q1 2023, worth a combined $3.93M — up 0.16% from $3.92M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of DMAC and 1 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 9 added.

The largest buyer was Cooperman Leon G, adding an estimated $88.7K. The largest seller was Dimensional Fund Advisors, cutting an estimated $40.7K.

  • 25 institutional investors held DiaMedica Therapeutics (DMAC) as of Q1 2023, down from 28 in Q4 2022.
  • Funds reported $3.93M of DiaMedica Therapeutics stock for Q1 2023, up 0.16% quarter-over-quarter.
  • 1 fund opened new DiaMedica Therapeutics positions in Q1 2023 and 4 closed out, a net change of -3 holders.
  • The largest DiaMedica Therapeutics buyer in Q1 2023 was Cooperman Leon G, an estimated $88.7K added.
  • The largest DiaMedica Therapeutics seller in Q1 2023 was Dimensional Fund Advisors, an estimated $40.7K sold.

Based on aggregated 13F filings for Q1 2023.